PPARA and hypertriglyceridemia: The PPARα agonist fenofibrate, which is approved for the treatment of hypercholesterolemia and hypertriglyceridemia, was shown to attenuate behavioral disruption and dopaminergic dysfunction in MIA offspring [53,54].